view1.1הכללת תרופות בסל נעשית עפי ... (נספח ב ' לנוהל זה ... באם המודל מתייחס לפרק זמן העולה על שנה,

  • View
    227

  • Download
    8

Embed Size (px)

Transcript

( , " 1994)

: 2017

: 53 13

1.

1.1 " , " . . , , .

, .

1.2 " .

1.3 ( , ) , .

:

, 309

' 39, .. 1176, 9101002

1.4 .

1.5 (" "):

.

/ .

1.6 " , .

1.7 .

.

.

1.8 .

.

pdf word

1.9 " sal@moh.health.gov.il

2.

2.1 3 :

I .

II .

III .

IV .

2.2 " .

.

2.3 .

2.4 , .

3.

3.1 I - :

3.1.1 .

3.1.2 ( ' 1 ' ) .

3.1.3 ( ).

3.1.4 .

3.1.5 ( ' 2) ( ' ) .

.

3.1.6 ( ' )

3.1.7 , ( ' ).

3.2 II :

3.2.1 ( ), .

3.2.2 ATC.

3.2.3 .

3.2.4 ( ).

3.2.5 .

3.2.6 , , .

3.2.7 / .

(supplements, appendix), .

3.2.8 , .

, , , .

:

"

: .

:

(RCT, , , / , / ), , (Phase II/III/IV), .

: , , , , .

(primary and secondary endpoints)

( ) :

X

Y

:

X

Y

HR

* .

Reference

3.2.9 .

3.2.10 - Cochrane.

3.2.11 .

.

. (abstracts) . (oral presentation ), , , . 12 .

3.2.12 ( ) .

, .

:

: ; ;

.

.

.

3.2.13 .

3.2.14 / , / , .

3.2.15 .

3.2.16 .

:

3.2.17 :

- , , .

- (compassionate use) , , .

- .

3.2.18 :

.

:

- .

-

.

- .

- ( /,

).

:

" " . " , .

:

, ."

" (' ' )

.

3.2.19 (PMS) ( PSUR- ).

3.2.20 , .

3.2.21 , -black box warnings.

3.2.22 .

3.2.23 , , .

3.2.24 , , (, ").

:

3.2.25 ( : , , , , ).

:

"

:

3.2.26 " ( ).

3.2.27 ( ) ( / ).

:

/

3.2.28 :

- , , .

- (compassionate use) , , .

- .

3.2.29 , NICE, SMC, , " ".

.

3.3 III :

3.3.1 :

* (prevalence): .

* (incidence): .

.

3.3.2 ( ) ( ").

3.3.3 .

3.3.4 .

3.3.5 ( / ) .

.

3.3.6 , ( , ).

3.3.7 ( ), .

3.4 IV :

3.4.1BUDGET IMPACT :

* ( ).

*, .

* (, , , ) .

* .

( ) :

/

" X

( ")

, , , "

( ) ( ")

3.4.2 (' ': " ").

1

( )

( / ,

1.

2.

3.

( )

( )

1.

2.

3.

4.

5.

6.

7.

/

:

, , ,

.

___________________________________________________________________

2

:

:

- ( ")*

:

- , , , , , .( ):

" ( ")

* .

____________________ __________________________ _____________

( ..)

'

/

/

( )

'

: |__|__|/|__|__|/|__|__|

-

___________ ___________, , , :

1. _________, , , , , / . , , , , .

2. 1 :

, : /

( , ) / , ( : ________________)

, /

, : /

, : /

, : /

() ____________________________________________________________________________________________________________________________________________________________________________________________________________

3. , , , , .

4. , , 1, / , , , .

5. , , ("-1998).

: __________________________________ :____________________

'

() .

" . " .

:

( , ")

(comparator) (standard of care)

- (cost-utility analysis)

(QALYs)

(time horizon)

3%

:

. .

" .

:

1. , , , , .

2. . , .

3. .

4. " .

5. ( ).

6. ( (decision tree), ') .

:

1. : , , , .

2. : , , , , , (, ).

3. : ( ), ( , ) .

4. : ( , )

5. : . , . , ( ), ( QALYs) , ( ), QALY .

I

:

, , , .

, , , ".

, , , , , , ". . ( ) .

, .

II -

( , ):

: (primary disease)

:

: . , , , , '.

: , , , ", , , '.

: .

: .

(contraindication) (warnings and precautions): .

III -

.

. . , " .

( ).

( ) , "do nothing", .

. , .

(' , ) ( , FEV1). , ( ) .

(Confidence Interval, CI). .

, / .

( ), .

.

.

, ( ' 1):

:

- (inclusion and exclusion), /

- .

:

- .

:

" . ( ) ( ) . , . ( ) , "do nothing", . -QALYs V.

1

1.

randomized controlled trial

(allocation):

double blind

(masking):

active

(control):

parallel

(assignment):

/ , 45-85. , .

(population under study):

efficacy

(endpoint):

Overall survival

(primary outcome measures):

Tumor response rate

Progression-free survival

(secondary outcome measures):

2 years

(length of follow-up):

(comparative safety):

2.

:

(population under study):

/ , 45-85. , .

(endpoint):

efficacy

(outcome measures):

Overall survival

(length of follow-up):

2 years

(comparative safety):

IV:

:

(),

,

.

( ), , , / . .

, , .

:

-

- / .

- , " .

/

/

, , ', , .

V:

(Quality Adjusted Life Years QALYs):

, QALYs, (utility) . QALYs, " . .

: https://research.tufts-nemc.org/cear/default.aspx

.

" 2.

, . ( Excel, TreeAge ') sal@moh.health.gov.il.

( ), (utility), (time horizon). , 3% .

, . . .

- IV, .

:

.

, . ( ) . , .

2: utility

Factor - both

Factor - female

Factor - male

AGE

Factor - both

Factor - female

Factor - male

AGE

0.828264

0.8216

0.8350

50

0.99325

0.9935

0.9930

0

0.823549

0.8165

0.8306

51

0.992334